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Abstract
While Chlamydia trachomatis infections are frequently asymptomatic, mechanisms that regulate host response to this
intracellular Gram-negative bacterium remain undefined. This investigation thus used peripheral blood mononuclear cells
and endometrial tissue from women with or without Chlamydia genital tract infection to better define this response. Initial
genome-wide microarray analysis revealed highly elevated expression of matrix metalloproteinase 10 and other molecules
characteristic of Type 2 immunity (e.g., fibrosis and wound repair) in Chlamydia-infected tissue. This result was corroborated
in flow cytometry and immunohistochemistry studies that showed extant upper genital tract Chlamydia infection was
associated with increased co-expression of CD200 receptor and CD206 (markers of alternative macrophage activation) by
endometrial macrophages as well as increased expression of GATA-3 (the transcription factor regulating TH2 differentiation)
by endometrial CD4+ T cells. Also among women with genital tract Chlamydia infection, peripheral CD3+ CD4+ and CD3+
CD4- cells that proliferated in response to ex vivo stimulation with inactivated chlamydial antigen secreted significantly more
interleukin (IL)-4 than tumor necrosis factor, interferon-c, or IL-17; findings that repeated in T cells isolated from these same
women 1 and 4 months after infection had been eradicated. Our results thus newly reveal that genital infection by an
obligate intracellular bacterium induces polarization towards Type 2 immunity, including Chlamydia-specific TH2
development. Based on these findings, we now speculate that Type 2 immunity was selected by evolution as the host
response to C. trachomatis in the human female genital tract to control infection and minimize immunopathological
damage to vital reproductive structures.
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Introduction
Chlamydia trachomatis is an obligate intracellular Gram-negative
bacterium that infects human ocular and genital epithelium.
Ocular C. trachomatis infection causes trachoma, an important
cause of preventable blindness whose earlier stages are often
asymptomatic [1]. Typically, C. trachomatis genital tract infection is
also asymptomatic, a feature enhancing its sexual transmission [2].
When untreated, female genital tract Chlamydia infection may
cause Fallopian tube damage that increases the risk of ectopic
pregnancy and infertility [3]. More often, however, even long-
standing infection is cleared in the absence of overt genital tract
damage, while advancing age is associated with increased
resistance to infection [4,5]. Such observations imply the
formation of Chlamydia-specific protective immunity and the
possibility of developing a prophylactic vaccine (provided better
understanding of human host response to natural C. trachomatis
genital tract infection is achieved).
In cogitation of a clinical picture signaling that C. trachomatis
infection does not elicit the robust inflammation that drives
differentiation of TH1 and TH17 immunity, our lab posited that
Type 2 immunity (including TH2-type responses) represents the
primary defense against Chlamydia in the human female genital
tract [6]. This hypothesis opposed current dogma, developed in
murine models of genital Chlamydia muridarum infection, which
maintains that response to C. trachomatis in the human genital tract
is similarly dominated by Type 1 immunity [7]. Providing context
for the formation and validity of our alternative hypothesis, Type 2
immunity is induced by numerous microbes that establish chronic
infection, creating tissue environments that dampen inflammation
and promote wound healing [8]. Playing a pivotal role in this
response are IL-4-secreting TH2 cells that stimulate macrophages
to promote tissue repair (i.e., alternative macrophage activation)
[9]. Although Type 2 immunity is established as an important
defense against extracellular parasites, its role against intracellular
parasites is not well explored. Offering preliminary, albeit indirect
evidence for the formation of Chlamydia-specific Type 2 immunity,
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our lab detected only short-lived TH1 and negligible TH17
Chlamydia-specific immunity among women with documented
history of C. trachomatis infection [10]. Because of these unremark-
able Chlamydia-specific TH1 and TH17 responses, in the current
study, peripheral blood mononuclear cells (PBMC) and endome-
trial tissue from women with or without genital C. trachomatis
infection were used to determine if this intracellular bacterium is
instead a more potent inducer of TH2 immunity. As posited, C.
trachomatis infection of genital tissue stimulated robust Type 2
immunity, including TH2 differentiation, alternative macrophage
activation, and increased expression of IL-24 and other molecules
enhancing tissue repair. Of equal importance, we observed that
secretion of IL-4, and not IFN-c or IL-17, was the principal
effector function of peripheral T cells responding to ex vivo
stimulation with chlamydial antigen. Taken together, these results
newly uncover exuberant Type 2 immunity elicited upon C.
trachomatis infection of the human female genital tract.
Results and Discussion
To begin our investigation of host response to C. trachomatis in
the human female genital tract, microarrays that compared gene
expression in uninfected and Chlamydia-infected endometrial tissue
were performed. Initial analysis of this data showed that Chlamydia
infection caused significant enrichment of canonical pathways
associated with Type 2 immunity [11], including pathways
involved in fibrosis and wound repair (Table 1). Moreover, 3 of
the 4 genes most highly upregulated in Chlamydia-infected tissue,
matrix metalloproteinase 10 (MMP10) (15-fold increase), IL-13a2
receptor (IL-13Ra2) (13-fold increase), and IL-24 (11-fold
increase), regulate biological functions that are characteristic of
Type 2 immunity (Figure 1 and Table 2). MMP-10, a
metalloproteinase produced by T cells in response to IL-4,
stimulates wound healing [12,13]; while interactions between IL-
13 to IL-13Ra2, also regulated by IL-4, promotes tissue repair by
increasing production of transforming growth factor-b1 [14,15].
Likewise, IL-24 secretion by monocytes and TH2 cells increases
the activity of signaling pathways responsible for wound healing
[16-18]. Endometrial Chlamydia infection also induced a 10-fold
increase in MUC5AC, a mucin gene expressed at low levels in
normal endometrial tissue but upregulated by IL-4 [19,20], and a
9-fold increase in aquaporin 4, an integral membrane protein
highly upregulated among individuals with asthma [21] (Table 2).
As microarray analysis showed C. trachomatis promotes exuber-
ant in situ differentiation of Type 2 immunity, we postulated this
pathogen must also elicit TH2-type responses. To test this
hypothesis, PBMC isolated from women with no Chlamydia
infection history or women with existing (at enrollment) and then
treated (at 1- and 4-month follow-up visits) endocervical or
endometrial Chlamydia infection were used in intracellular cytokine
staining (ICS) assays that used flow cytometry to delineate the
effector function of T cells responding to stimulation with
inactivated C. trachomatis elementary bodies (EB). As predicted,
CD3+ cells in these assays from women with existing or treated
Chlamydia infection proliferated in response to stimulation with
inactivated EB (Figure S1). Interestingly, proliferation was more
robust at the 1-month follow-up visit than at the enrollment or 4-
month follow-up visits (Figure 2). Calculating the adjusted
percentages of cytokines produced by peripheral CD3+ CD4+ or
CD3+ CD4- cells that proliferated in response to EB, we saw
negligible production of IL-17 in samples from uninfected and
Chlamydia-infected women at all study visits (Figure 3). Conversely,
there was enhanced intracellular accumulation of IFN-c and TNF
by proliferating CD3+ CD4+ and CD3+ CD4- cells from Chlamydia-
infected women, but only in specimens collected at the 1-month
follow-up visit (Figure 3). Interestingly, these results were
congruent with our recently published cross-sectional study in
which peripheral blood specimens obtained from Chlamydia-
infected women 30-60 d after starting a Chlamydia-specific
antimicrobial displayed a higher frequency of CD4+ cells
producing IFN-c in response to EB stimulation compared to
specimens collected ,30 d or . 60 d after starting therapy [10].
Even more interesting, in the current investigation we also found
that intracellular IL-4 accumulation by proliferating CD3+ CD4+
and CD3+ CD4- cells in PBMC samples from Chlamydia-infected
women at enrollment, 1-month, and 4-month visits were all
significantly higher than in uninfected controls (Figure 3 and
Figure S2). This indicated that Chlamydia-specific T cells were
preferentially polarized towards a TH2 profile, and together with
our earlier publication, suggested that Chlamydia-specific TH1
immunity develops more slowly, is more transient, and is perhaps
a less biologically relevant host response than Chlamydia-specific
TH2 immunity.
Based on the substantial TH2 response elicited in EB-stimulated
peripheral T cells, we further posited that CD4+ cells in Chlamydia-
infected tissue are polarized towards a TH2 profile. To test this
hypothesis, IHC was used to examine CD4+ cell expression of T-
bet and GATA-3 (transcription factors regulating TH1 and TH2
differentiation, respectively) in paraffin-embedded endometrial
biopsy sections from women without current Chlamydia, Neisseria
gonorrhoeae, or Trichomonas vaginalis infection and women with extant
upper genital tract Chlamydia infection. As predicted by our ICS
assay results, each Chlamydia-infected tissue section demonstrated
greater expression of GATA-3 than T-bet (representative results
shown in Figure 4). Interestingly, expression of GATA-3, but not
T-bet, was present in uninfected tissue, indicative of the role this
transcription factor plays in estrogen receptor-responsive tissue
[22]. Conversely, inspection of five high-powered (X200) fields per
specimen revealed GATA-3+ CD4+ cell numbers were signifi-
cantly higher in Chlamydia-infected vs. uninfected tissue (Figure 5).
Taken together, these IHC findings were consistent with
preferential secretion of IL-4 by EB-stimulated peripheral T cells
from women with extant Chlamydia infection (Figure 3).
Prompted by these results, we returned to our microarray data
to examine endometrial transcription factor expression. Based on
the high levels of GATA-3 levels expressed in uninfected and
Chlamydia-infected endometria (Figure 4 and Figure 5), it was not
surprising that Chlamydia infection induced no significant fold-
change in GATA-3 expression. On the other hand, expression of
several macrophage-associated transcription factors was signifi-
cantly modulated by Chlamydia infection (Tables 3 and 4). This
included increased expression of peroxisome proliferator-activated
receptor gamma (PPARG), which promotes polarization of
macrophages to the M2 phenotype [23]. As TH2 immunity
stimulates macrophages that promote fibrosis, tissue remodeling,
and wound repair (alternative macrophage activation) [24,25], we
hypothesized that macrophages in Chlamydia-infected endometrial
tissue display evidence of alternative activation. As predicted, flow
cytometry studies showed macrophages in endometria with extant
Chlamydia infection significantly increased their expression of the
CD200R, a marker of alternative macrophage activation and a
negative regulator of classical macrophage activation (Figure 6)
[26]. Because CD200R binding triggers macrophages to dampen
inflammation and suppress collateral damage to host tissue during
chronic microbial infection [27-29], increased expression of
CD200R by macrophages in Chlamydia-infected tissue is consistent
with the clinical presentation of an infection that persists in genital
tract epithelial cells without eliciting overt inflammatory changes.
Chlamydia Promotes Type 2 Immunity
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Furthermore, we found that Chlamydia infection increased the
percentage of endometrial macrophages co-expressing CD200R
and CD206 (mannose receptor), another classic marker of
alternative macrophage activation (Figure 6) [30]. In addition,
Chlamydia infection promoted increased macrophage expression of
CD40, a costimulatory molecule critical for induction of B cell
responses in mucosal tissue [31]. This result correlated with our
microarray findings showing Chlamydia-infected endometrial tissue
had significant enrichment of the B cell development pathway
(Table 1) and significantly increased expression of Pax5, a
transcription factor essential for commitment to the B lymphocyte
lineage [32,33] (Table 4).
In conclusion, the picture of the host response to Chlamydia
infection of the human female genital tract emerging from our lab
is a response skewed towards Type 2 immunity, including
differentiation of IL-4-secreting CD3+ CD4+ and CD3+ CD4-
cells and stimulation of alternative macrophage activation.
Clearly, further interrogation of the phenotype and function of
these CD3+ CD4+ and CD3+ CD4- cells is needed, and is an area
of active research in our lab. On the other hand, as Chlamydia host
defense in humans is still thought dominated by highly inflamma-
Table 1. Canonical pathways significantly enriched (P , 0.01) in endometrial tissue of women with endometrial C. trachomatis
infection vs. endometrial tissue of women with no existing upper or lower genital tract infection.
Ingenuity Canonical Pathways
-log (p),










Hepatic Fibrosis / Hepatic Stellate Cell Activation 6.03 22 9 82
B Cell Development 4.34 10 0 71
Primary Immunodeficiency Signaling 3.23 11 0 196
Communication between Innate and Adaptive Immune Cells 2.72 14 0 65
Hematopoiesis from Pluripotent Stem Cells 2.51 9 0 61
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 2.20 25 11 248
Acute Myeloid Leukemia Signaling 2.19 8 6 120
TREM1 Signaling 2.18 10 1 51
Metabolism of Xenobiotics by Cytochrome P450 2.11 12 1 95
Glycosphingolipid Biosynthesis – Neolactoseries 2.06 6 0 67
Autoimmune Thyroid Disease Signaling 2.04 8 0 95
Systemic Lupus Erythematosus Signaling 2.00 21 3 50
Amyotrophic Lateral Sclerosis Signaling 1.90 12 3 42
MSP-RON Signaling Pathway 1.89 8 1 151
Crosstalk between Dendritic Cells and Natural Killer Cells 1.85 14 0 206
GM-CSF Signaling 1.83 8 3 92
Allograft Rejection Signaling 1.82 8 0 526
Graft-versus-Host Disease Signaling 1.82 8 0 239
Thyroid Cancer Signaling 1.75 4 4 128
eNOS Signaling 1.74 13 5 74
Arachidonic Acid Metabolism 1.73 13 1 207
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 1.67 12 0 63
G-Protein Coupled Receptor Signaling 1.65 45 6 28
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 1.65 17 10 109
PTEN Signaling 1.60 13 3 89
Role of PI3K/AKT Signaling in the Pathogenesis of Influenza 1.53 7 3 49
Dendritic Cell Maturation 1.48 16 5 142
Nur77 Signaling in T Lymphocytes 1.40 8 0 84
Glycosphingolipid Biosynthesis – Lactoseries 1.39 3 0 79
Natural Killer Cell Signaling 1.39 11 3 82
Small Cell Lung Cancer Signaling 1.37 9 2 71
Docosahexaenoic Acid (DHA) Signaling 1.35 5 2 196
Ovarian Cancer Signaling 1.34 10 7 65
VEGF Family Ligand-Receptor Interactions 1.33 7 4 61
Non-Small Cell Lung Cancer Signaling 1.31 7 3 248
Eicosanoid Signaling 1.30 22 9 120
doi:10.1371/journal.pone.0058565.t001
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tory Type 1 immunity [7,34], our findings already communicate
that development of a safe and effective C. trachomatis vaccine will
require new understanding of immune responses elicited by
natural infection and Chlamydia-specific immune responses that
protect against infection and immunopathological tissue damage.
Our study was responsive to the first requisite, offering fresh
information about host responses elicited against this obligate
intracellular bacterium in the human female genital tract.
Regarding the second requisite, our recent [10] and current work
implies that Type 2 immunity was evolutionarily selected to
control genital C. trachomatis infection and minimize immunopath-
ological damage to vital reproductive anatomy. Our work also
supports prior observation that IL-13 production by PBMC
stimulated with chlamydial antigen correlated with enhanced
resistance to Chlamydia genital tract re-infection in women [35].
However, only additional work will resolve if Chlamydia-specific
Type 2 immunity is sterilizing or if Type 2 immunity plays a role
in host defense against other intracellular bacterial pathogens.
Methods
Ethics Statement
The University of Pittsburgh’s Institutional Review Board
approved our study design and procedures (PRO0611062)
(PRO09070184) (PRO10010159), and written informed consent
was obtained from individuals prior to their participation. While
minors/children were eligible for enrollment, none were enrolled
and none were assented/consented for enrollment.
Participants and procedures
Nonpregnant women 15–35 years old at high risk for genital
tract infection were eligible for enrollment, while women
presenting with symptoms of pelvic inflammatory disease were
not. In a separate study, nonpregnant women 18–40 years old that
denied history of Chlamydia infection were also prospectively
enrolled. After participants signed written informed consent, at
least 40 ml of peripheral venous blood was collected into sodium
heparin-containing blood tubes (Becton-Dickinson). Peripheral
blood that was collected from 7 women (average age = 24.6 years)
enrolled with no history of Chlamydia infection and 14 women
(average age = 20.8 years) enrolled with existing Chlamydia
infection (and also collected 1 and 4 months after treatment of
infection with 0.25 g ceftriaxone IM and 1 g azithromycin) was
used to isolate PBMC by density gradient centrifugation, and these
cells were stored in liquid nitrogen prior to their use in ICS assays
measuring the effector function of cells that proliferated in
response to chlamydial antigen [10,36]. Cervical swab and
endometrial biopsy specimens were used to identify C. trachomatis
and N. gonorrhoeae infection by nucleic acid amplification testing
(NAAT), and vaginal swabs were obtained for T. vaginalis detection
also by NAAT. In women that returned for follow-up visits,
absence of these 3 genital tract infections was confirmed with
similar testing. Oligonucleotide-based genome array studies
utilized endometrial biopsy specimens from 10 women with no
current infection and 12 women with existing endometrial
Figure 1. Genome-wide microarray analysis shows C. trachoma-
tis elicits robust Type 2 immunity. Compared to expression in
uninfected controls, endometrial tissue from women with existing
endometrial Chlamydia infection displayed 15-fold, 13-fold, and 11-fold
increases in the expression of MMP-10, IL-24, and IL-13Ra2, respectively.
These genes, each with biological activity linked to Type 2 immunity,
were 3 of the 4 most dramatically upregulated genes in Chlamydia-
infected tissue. Significance of differences between groups was
determined by use of Dunn’s test (see Methods section for further
details regarding statistical considerations). Open circles indicate
samples from uninfected controls (n = 10); gray circles indicate samples
from women with existing endometrial Chlamydia infection (n = 12)
(horizontal bars indicate median values for each group).
doi:10.1371/journal.pone.0058565.g001
Table 2. List of the 20 molecules (and corresponding fold
change) that were identified by genome-wide microarray
analysis as the most intensely upregulated by endometrial C.
trachomatis infection.
Entrez Gene Name Fold change
matrix metallopeptidase 10 (stromelysin 2) 15.19
interleukin 24 13.40
corneodesmosin 12.61
interleukin 13 receptor, alpha 2 11.30
hydroxycarboxylic acid receptor 3 10.00
tripartite motif containing 48 10.00
thyroglobulin 9.85
tumor necrosis factor receptor superfamily, member 11b 9.71
pecanex homolog (Drosophila) 9.68
mucin 5AC, oligomeric mucus/gel-forming 9.54
carcinoembryonic antigen-related cell adhesion molecule 7 9.32
bone morphogenetic protein 15 9.09
desmocollin 3 9.89
mucin 3B, cell surface associated 8.81
dopamine receptor D5 8.80
cutaneous T-cell lymphoma-associated antigen 1 8.66
recombination activating gene 1 8.56
aquaporin 4 8.56
killer cell immunoglobulin-like receptor, three domains, X1 8.48
uncharacterized LOC100507630 8.45
doi:10.1371/journal.pone.0058565.t002
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Chlamydia infection (and without extant Neisseria or Trichomonas
infection as identified by NAAT). Endometrial tissue from 4
women without existing NAAT-detected genital infection and 14
women with current Chlamydia infection was used to assess
macrophage phenotype by flow cytometry, while paraffin-embed-
ded endometrial tissue from 4 women without existing genital
infection and 6 women with current endometrial Chlamydia
infection was used to evaluate T cell expression of T-bet and
GATA-3 by immunohistochemistry (IHC).
Microarray studies
Endometrial tissue from 10 women with no identified genital
infection and 12 women with existing C. trachomatis endometrial
infection (but no other identified infection) was dissociated into
single-cell suspension or placed into RNAlater (Qiagen). Samples
underwent total RNA purification using the Qiagen RNeasy Mini
Kit in accordance with manufacturer’s instructions and were
suspended in nuclease-free water. Inclusion in ensuing in vitro
amplification assays required a spectrophotometric 260/280
absorption ratio . 1.8 as determined using a NanoDrop
spectrophotometer (Thermo Scientific). RIN (RNA Integrity
Index) values were determined via electrophoretic analysis (Agilent
Bioanalyzer 2100, Agilent Technologies) (results ranged between
5–8). Amplifications were performed with 100 ng total RNA using
the NuGEN whole transcription approach involving use of the
Ovation FFPE WTA assay (NuGEN) that employed random 3’
primers to eliminate amplification bias. Confirmation of cDNA
diversity for each amplification reaction was obtained using the
Bioanalyzer 2100 to generate an electrophoretogram regarding
sample yield, integrity, and size diversity against a laboratory
human RNA standard and a Universal Human Reference RNA
(Stratagene). 5 mg of purified cDNA was incubated with fragmen-
tation buffer (NuGEN) for 30 m at 37uC, then 2 m at 95uC. Each
cDNA sample underwent hybridization on Affymetrix GeneChip
HG U133A 2.0 arrays that contained transcripts representing the
functionally characterized human genome. In summary of this
process, fragmented cDNA was combined with water in hybrid-
ization cocktails to a final volume of 220 ml, and 130 ml of this
cocktail was hybridized on each array for 18 h at 45uC. Arrays
were washed, stained with streptavidin-phycoerythrin in a
GeneChip Fluidics Station 450 (Affymetrix), and scanned using
a GeneChip Scanner 3000 (Affymetrix). Quality control param-
eters were derived from the MAS 5.0 algorithm of the Expression
Console software (v. 1.2.0.20; Affymetrix), and expression data
derived from raw intensity files generated by this algorithm. Of
22,277 chip panels (i.e., transcript sequences) gauged, 7,759 panels
showed $ 2-fold change in average gene expression between
infected and uninfected tissue. Among such panels, we required
the higher expressing group to show detectable transcript (i.e., a
‘‘Present’’ call) in at least 2/3 of samples (i.e., 7 of 10 for uninfected
controls and 8 of 12 for infected women). Dunn’s test was then
used to determine significance of the differences between the two
groups. Selecting differences between mean ranks greater than
5.45 (a = 0.05) identified 1329 panels, representing 1087 unique
characterized genes which have Gene Symbols listed at the http://
www.ncbi.nlm.nih.gov/gene website. These 1329 panels were
submitted to the Ingenuity Pathways Analysis website which
parsed data into 36 significantly enriched canonical pathways
consisting of 509 occurrences of 206 unique, characterized genes.
Microarray data was deposited to Gene Expression Omnibus
(GEO) repository under accession number GSE41075, following
MIAME (Minimum Information About a Microarray Experiment)
guidelines.
Flow cytometry studies
For ICS assays, C. trachomatis serovar D elementary bodies (EB)
were inactivated by c-irradiation (lack of infectivity confirmed by
an absence of inclusion forming units (IFU) when EB doses
equivalent to 107 IFU were inoculated onto HeLa cell monolayers
and incubated 48 h at 37uC/5% CO2). As described elsewhere,
PBMC labeled with CellTraceTM Violet cell proliferation dye
(Invitrogen) were stimulated with inactivated EB to allow
simultaneous quantification of IFN-c, TNF, IL-4, and IL-17
production by T cells that proliferated in response to chlamydial
Figure 2. The ability of peripheral T cells from women with existing or treated Chlamydia infection to proliferate in response to
stimulation with C. trachomatis elementary bodies (EB) decreased 4 months after antimicrobial administration. Peripheral blood
mononuclear cells (PBMC) isolated from women at enrollment and at 1 and 4 m follow-up visits were cultured 96 h in presence of inactivated EB or
media alone. Proliferation of (A) CD3+CD4+ and (B) CD3+CD4- cells was assessed by flow cytometry using stimulation indexes calculated as described
in Methods section. Stratification of Chlamydia-infected women by time since diagnosis and treatment of infection showed T cell proliferation was
higher 1 month after treatment compared to enrollment, and that proliferative capacity diminished 4 months after treatment. Stimulation indexes of
samples from Chlamydia-infected women (n = 14) at indicated visits were compared to those from women with no known history of infection (n = 7)
using one-way ANOVA and Dunnett’s multiple comparison test (horizontal bars indicate means).
doi:10.1371/journal.pone.0058565.g002
Chlamydia Promotes Type 2 Immunity
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e58565
Chlamydia Promotes Type 2 Immunity
PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e58565
antigen [36]. Isotype controls were included to establish gates that
determined intracellular cytokines production by live CD3+ CD4+
or CD3+ CD4- cells. Stimulation indices were calculated as the
quotient of (% CD3+CD4+ or CD3+ CD4- cells proliferating in
cultures that received EB) and (% CD3+CD4+ or CD3+CD4- cells
proliferating in unstimulated cultures). An adjusted percentage of
proliferating, cytokine-producing CD3+CD4+ or CD3+CD4- cells
was calculated as the difference between [(% CD3+CD4+ or
CD3+CD4- cells proliferating in cultures that received EB) (%
cytokine-producing CD3+CD4+ or CD3+CD4- cells proliferating
in cultures that received EB)] and [(% CD3+CD4+ or CD3+CD4-
cells proliferating in unstimulated cultures) (% cytokine-producing
CD3+CD4+ or CD3+CD4- cells proliferating in unstimulated
cultures)]. Normality of the data was determined using the
D’Agostino–Pearson omnibus test, and statistical tests chosen
based on data distribution and the number of comparisons made
(p values , 0.05 were considered significant). As applicable, T cell
proliferation was compared with 1-tailed Wilcoxon matched-pair
signed rank tests or 1-way ANOVA and Dunnett’s method for
multiple comparisons. Intracellular cytokine levels were compared
with Friedman or Kruskal-Wallis tests and, as indicated, Dunn’s
post-hoc test. For macrophage phenotype assays, cryopreserved
endometrial cells were thawed and processed at ice-cold temper-
atures. Single-cell suspensions were stained with LIVEa˜ DEADH
fixable aqua dead cell stain (Invitrogen), and incubated with
various combinations of the following optimally titrated monoclo-
nal antibodies: FITC-conjugated anti-HLA-DR FITC (G46-6),
PE-conjugated anti-CD163 (HGI/61), PE-Cy7-conjugated anti-
CD80 (L307.2), PerCP-Cy5.5-conjugated anti-CD45 (2D1), APC-
conjugated anti-CD40 (5C3), V500-conjugated anti-CD15 (HI98)
(all BD Biosciences); PE-Cy7-conjugated anti-CD209 (eB-h209),
Figure 3. TH2-type immunity dominates host response to C. trachomatis infection. PBMC were isolated from women with no history of
Chlamydia infection (n = 7) and women with an existing endocervical or endometrial Chlamydia infection (n = 14) at enrollment and again from the
latter women 1 and 4 months after initiating an anti-chlamydial antimicrobial. Flow cytometric analysis of intracellular cytokine staining (ICS) allowed
comparison of EB-stimulated (A) CD3+CD4+ and (B) CD3+CD4- T cells that proliferated and produced IFN-c, TNF, IL-4, or IL-17 (calculation described in
Methods section). The adjusted percentages of cytokines that were produced in response to EB stimulation among uninfected and infected women
were compared using Kruskal-Wallis’ test and Dunn’s post-hoc test (horizontal bars indicate medians). Grey boxes indicate pairs considered in the
comparison for each p value displayed, and significant p values are indicated in bold characters.
doi:10.1371/journal.pone.0058565.g003
Figure 4. Endometrial Chlamydia infection is associated with
the presence of CD4+ T cell aggregates and high expression of
the TH2 transcription factor GATA-3. Sequential sections of
paraffin-embedded endometria from women with no identified C.
trachomatis, N. gonorrhoeae, or T. vaginalis lower or upper genital tract
infection (n = 4) or with endometrial C. trachomatis infection (n = 6)
were used to immunohistochemically evaluate T-bet or GATA-3
expression (both DAB), and the presence of CD4+ mononuclear cells
(Vector Red) as described in Methods section. Aggregates of GATA-3+
(but not T-bet+) and CD4+ mononuclear cells were seen in endometrial
stroma of Chlamydia-infected tissue (representative micrographs shown
at X200 magnification). Moreover, only a few CD4+ mononuclear cells
were present in uninfected endometrial tissue even tough GATA-3 was
expressed at high levels in both instances. Right panels show images
displaying DAB or Vector Red staining and hematoxylin as counterstain,
while left panels show DAB or Vector Red layer alone.
doi:10.1371/journal.pone.0058565.g004
Figure 5. Endometrial Chlamydia infection causes infiltration of
CD4+ T cells expressing GATA-3. Sections of paraffin-embedded
endometria from women with no identified C. trachomatis, N.
gonorrhoeae, or T. vaginalis lower or upper genital tract infection
(n = 4) or with endometrial C. trachomatis infection (n = 6) were utilized
to simultaneously detect the expression of GATA-3 (DAB) and CD4
(Vector Red) using immunohistochemistry, as described in Methods
section. (A) In uninfected endometrial tissue, we observed scarce
numbers of CD4+ cells coexpressing GATA-3, however, in endometrial
tissue from Chlamydia-infected women the presence of aggregates of
GATA-3+ CD4+ mononuclear cells was patent (representative micro-
graphs shown at X200 magnification). Upper left panels show images
displaying Vector Red staining, while upper right panels show images
displaying DAB staining as defined by spectral analysis. Lower right
panels show original images used in analysis, and lower left panels
show images in which GATA-3 and CD4 colocalization areas have been
digitally highlighted (light blue). Circles delineate areas of highest
colocalization in images shown. (B) Colocalization of CD4+ areas within
GATA-3+ areas increases dramatically with Chlamydia infection,
indicating that endometrial Chlamydia infection drives the infiltration
of GATA-3+CD4+ T cells that form aggregates. Each symbol represents
the percentage of colocalization observed in a single field. Matching
colors indicate all the fields evaluated from one specimen. Comparison
was performed using a two-tailed Mann-Whitney test (horizontal bars
indicate medians).
doi:10.1371/journal.pone.0058565.g005
Chlamydia Promotes Type 2 Immunity
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e58565
APC-eF780-conjugated anti-CD14 (61D3), eF450-conjugated
anti-CD206 (19.2) (all eBioscience); PE-conjugated anti-CD64
(10.1), BV421-conjugated anti-CD86 (IT2.2) (all BioLegend); and
AF647-conjugated anti-CD200R (OX108) (AbD Serotec). Cells
were washed and fixed in BD CytofixTM Fixation Buffer (BD
Biosciences). Relative expression of the different markers in
macrophages present in endometrial tissue from uninfected or
women with upper or lower genital tract Chlamydia infection was
compared using the unpaired, one-tailed Student t-tests with
Welch’s correction. In flow cytometry studies, cells were collected
on a LSR II cytometer (BD Biosciences), and evaluated using
FACSDiva (BD Biosciences) and FlowJo (Tree Star) software.
Statistical analyses were performed using PrismH 6 software
(GraphPad), and figure legends specify the particular statistical
analysis performed.
For ICS assays, C. trachomatis serovar D elementary bodies (EB)
were inactivated by c-irradiation (lack of infectivity confirmed by
an absence of inclusion forming units (IFU) when EB doses
equivalent to 107 IFU were inoculated onto HeLa cell monolayers
and incubated 48 h at 37uC/5% CO2). As described elsewhere,
PBMC labeled with CellTraceTM Violet cell proliferation dye
(Invitrogen) were stimulated with inactivated EB to allow
simultaneous quantification of IFN-c, TNF, IL-4, and IL-17
production by T cells that proliferated in response to chlamydial
antigen [36]. Isotype controls were included to establish gates that
determined intracellular cytokines production by live CD3+ CD4+
or CD3+ CD4- cells. Stimulation indices were calculated as the
quotient of (% CD3+CD4+ or CD3+ CD4- cells proliferating in
cultures that received EB) and (% CD3+CD4+ or CD3+CD4- cells
proliferating in unstimulated cultures). An adjusted percentage of
proliferating, cytokine-producing CD3+CD4+ or CD3+CD4- cells
was calculated as the difference between [(% CD3+CD4+ or
CD3+CD4- cells proliferating in cultures that received EB) (%
cytokine-producing CD3+CD4+ or CD3+CD4- cells proliferating
in cultures that received EB)] and [(% CD3+CD4+ or CD3+CD4-
cells proliferating in unstimulated cultures) (% cytokine-producing
CD3+CD4+ or CD3+CD4- cells proliferating in unstimulated
cultures)]. Normality of the data was determined using the
D’Agostino–Pearson omnibus test, and statistical tests chosen
based on data distribution and the number of comparisons made
(p values , 0.05 were considered significant). As applicable, T cell
proliferation was compared with 1-tailed Wilcoxon matched-pair
signed rank tests or 1-way ANOVA and Dunnett’s method for
multiple comparisons. Intracellular cytokine levels were compared
with Friedman or Kruskal-Wallis tests and, as indicated, Dunn’s
post-hoc test. For macrophage phenotype assays, cryopreserved
endometrial cells were thawed and processed at ice-cold temper-
atures. Single-cell suspensions were stained with LIVEa˜ DEADH
fixable aqua dead cell stain (Invitrogen), and incubated with
various combinations of the following optimally titrated monoclo-
nal antibodies: FITC-conjugated anti-HLA-DR FITC (G46-6),
PE-conjugated anti-CD163 (HGI/61), PE-Cy7-conjugated anti-
CD80 (L307.2), PerCP-Cy5.5-conjugated anti-CD45 (2D1), APC-
conjugated anti-CD40 (5C3), V500-conjugated anti-CD15 (HI98)
(all BD Biosciences); PE-Cy7-conjugated anti-CD209 (eB-h209),
APC-eF780-conjugated anti-CD14 (61D3), eF450-conjugated
anti-CD206 (19.2) (all eBioscience); PE-conjugated anti-CD64
(10.1), BV421-conjugated anti-CD86 (IT2.2) (all BioLegend); and
AF647-conjugated anti-CD200R (OX108) (AbD Serotec). Cells
were washed and fixed in BD CytofixTM Fixation Buffer (BD
Biosciences). Relative expression of the different markers in
macrophages present in endometrial tissue from uninfected or
women with upper or lower genital tract Chlamydia infection was
compared using the unpaired, one-tailed Student t-tests with
Welch’s correction. In flow cytometry studies, cells were collected
on a LSR II cytometer (BD Biosciences), and evaluated using
Table 3. Transcription factors identified by Ingenuity Pathway Analysis as modulated by endometrial C. trachomatis infection
(determined by downstream target pools). *
Transcription factor Fold modulation -log (p), i.e. 2 ; p , 0.01 # Genesmodulated
CEBPA 3.35 6.40 10
ESR1 –2.60 2.23 10
FHL2 –2.18 2.24 5
LEF1 –4.62 1.81 8
NFATC1 2.30 3.52 10
NPAT 5.98 1.71 2
NRIP1 –2.67 1.63 9
PAX8 2.27 1.50 5
PGR –3.78 1.44 10
RUNX1 3.31 1.40 9
RUNX2 2.04 2.83 10
RUNX3 2.52 5.15 10
SMARCA2 –2.40 1.69 8
TCF3 –2.08 1.57 10
TCF7 2.74 1.71 7
TEAD1 –2.32 1.42 4
TP63 6.38 3.92 10
VDR 4.14 1.58 10
*Ingenuity Pathway Analysis identified 18 known transcription factors that were modulated by endometrial C. trachomatis infection whose known downstream targets
were significantly enriched among modulated genes. Above table lists those transcription factors, representing 147 occurrences of 96 target genes.
doi:10.1371/journal.pone.0058565.t003
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FACSDiva (BD Biosciences) and FlowJo (Tree Star) software.
Statistical analyses were performed using PrismH 6 software
(GraphPad), and figure legends specify the particular statistical
analysis performed.
IHC studies
Paraffin-embedded endometrial tissues from uninfected women
and women with extant endometrial Chlamydia infection (but no
other identified genital tract infection) were stained with polyclonal
antibodies detecting GATA-3 or T-bet (both Abcam) and/or a
monoclonal antibody detecting CD4 (Dako). This was followed by
signal detection that used brown 3,3’ diamino benzidine (DAB)
(Dako) and Vector Red (Vector), respectively. For subsequent
evaluation, conventional bright field images were acquired using a
Cri Nuance spectral analyzer (CRi), and resultant images used to
reconstruct multiple spectral distributions and define the intensity
and overlap of DAB and Vector Red staining per pixel using CRi
Nuance software. Staining intensities were then converted to
composite false color images. Finally, to determine relative
frequency of CD4+ areas overlapping GATA-3+ areas five random
fields (X200) that contained intact tissue were analyzed per
specimen.
Supporting Information
Figure S1 Peripheral T cells from women with existing
or treated Chlamydia infection proliferated in response
to stimulation with C. trachomatis elementary bodies
(EB). Peripheral blood mononuclear cells (PBMC) isolated from
women at enrollment and 1-month and 4-month follow-up visits
were cultured 96 h in presence of inactivated EB or media alone
for 96 h. (A, B) T cells from women with no history of Chlamydia
infection (n= 7) did not show increased proliferation in response to
chlamydial antigen stimulation. (C, D) Peripheral CD3+CD4+ and
CD3+CD4- cells from women with existing or treated Chlamydia
infection (total n = 42, representing the 3 samples taken at
indicated time points from 14 women) significantly increased
proliferation in response to EB stimulation. Comparisons were
made using one-tailed Wilcoxon matched-pairs signed rank test.
Open circles represent results from samples not exposed to
chlamydial antigen; gray circles represent samples that were
stimulated with inactivated EB.
(PDF)
Figure S2 IL-4 is the predominant and most persistent
cytokine produced by peripheral T cells that proliferat-
ed in response to ex vivo stimulation with inactivated
EB. PBMC were cryopreserved from women with an existing
endocervical or endometrial Chlamydia infection (n = 14) at
enrollment and again 1 and 4 months after their initiation of
anti-chlamydial antimicrobial therapy. Cells were thawed, cul-
tured 96 h in the presence of inactivated EB, and processed for
flow cytometric evaluation of IFN-c, TNF, IL-4, and IL-17
production as described in Methods section. Total cytokine
secretion was determined for CD3+CD4+ (A) and CD3+CD4- (B)
Table 4. Transcription factors identified by Ingenuity Pathway Analysis as modulated by endometrial C. trachomatis infection
(determined by z-score). *
Transcription factor
Activation z-score
(must be . 2)
-log (p), i.e. 2 ; p
, 0.01 Changes consistent
NFkB (complex) 5.98 6.69 49 of 72
SP1 3.42 6.49 25 of 65
CEBPA 3.30 6.40 33 of 54
AHRa 2.13 5.13 25 of 41
NCOA1 2.53 5.00 10 of 16
ETS1 3.40 4.37 14 of 29
SPI1 2.50 4.01 12 of 25
TP63 3.35 3.92 19 of 34
STAT1 3.13 3.75 20 of 30
JUN 2.15 3.68 18 of 44
HIF1A 2.58 3.58 22 of 38
SPDEF 2.71 3.50 10 of 14
TP53 2.18 3.00 51 of 103
RELA 2.42 2.98 17 of 37
PPARG 2.17 2.75 21 of 40
FOS 3.00 2.73 20 of 53
CREBBP 2.08 2.66 15 of 25
PAX5 2.17 2.47 5 of 7
RELB 2.19 2.34 7 of 10
EPAS1 2.65 2.28 13 of 21
*Ingenuity Pathway Analysis identified changes in transcription factor activity in the absence of altered transcription factor expression by detecting significantly
enriched downstream targets and then confirming that the direction of expression change for each target was in agreement with the known effect (z-score).
aIn addition to the transcription factors discussed in the body of text, Chlamydia infection was associated with increased expression of the aryl hydrocarbon receptor, a
molecule induced by IL-4 in human B cells [37].
doi:10.1371/journal.pone.0058565.t004
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Figure 6. Endometrial Chlamydia infection promotes alternative activation of macrophages. Endometrial tissue from women with no
identified C. trachomatis, N. gonorrhoeae, or T. vaginalis lower or upper genital tract infection (n = 4), or from women with endocervical or endometrial
C. trachomatis infection (n = 14 for Panel A; n = 12 for Panel B) were processed for flow cytometric analysis as described in Methods section.
Macrophages were identified as FSC-AintSSC-AintCD45+CD15-CD14+HLA-DR+ live cells (as depicted in Figure S3), and 2 monoclonal antibody panels
were used to interrogate macrophage differentiation and activation. Panel (A) evaluated expression of CD163, CD209, CD200R and CD206, while
panel (B) evaluated expression of CD64, CD80, CD40 and CD86. Comparisons were done using unpaired one-tailed Student t-tests with Welch’s
correction (horizontal bars indicate mean values for each group and significant p values are indicated in bold characters). Open circles indicate
samples from uninfected controls; light gray circles indicate samples from women with cervical Chlamydia infection; and dark gray circles indicate
samples from women with endometrial Chlamydia infection. Representative contour plots of CD200R, CD206, CD40 and CD80 expression by
endometrial macrophages are displayed next to figures. For CD200R and CD206 expression evaluation (A), representative flow plots from peripheral
blood monocytes treated with IL-4 (100 U/ml) for 24 hours and the corresponding untreated control are also shown.
doi:10.1371/journal.pone.0058565.g006
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cells that proliferated in response to inactivated EB, and
comparisons performed using Friedman test and Dunn’s post-
hoc test (horizontal bars indicate medians). Grey boxes indicate
the pairs considered in the comparison for each indicated p value,
and significant p values are indicated in bold characters.
(PDF)
Figure S3 Gating strategy used to identify macrophages
infiltrating endometrial tissue. Cryopreserved endometrial
cells were processed for flow cytometric analysis as described in
Methods section. Contour plots depict the gating strategy used to
define macrophage populations within endometrial cell suspen-
sions. Plots show in sequence the gating hierarchy used to
interrogate for CD45+, live non-CD15+ cells, singlets, and finally
to define the macrophage population as CD14+HLA-DR+(red
gate). Representative contour plots displaying expression of some
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